“The $706 Billion
Private Deal Briefing”

Dear Investor,

Just days from now, you’ll have a rare chance to claim early private shares … in a company driving one of the most important medical advancements in decades.

Something that could transform the world of health forever.

The Journal of Medicinal Chemistrycalls it “a paradigm shift” …And The Lancet, one of the world’s most prestigious medical journals, says “This single innovation has upended decades of pharmaceutical thinking …”.

And CPC Scientific calls it “the new growth frontier.” 

This disruption has offered early investors a chance at returns as high as 6,582%, 11,955%, 37,989% or more …

But this time, the rewards for early investors could be even more exciting.

All thanks to a tech breakthrough that’s about to disrupt multiple markets valued at over $700 BILLION dollars.

If you’re just hearing about this now, don’t worry. Because there is one little-known company in this sector that stands head and shoulders above anything else …

And starting Tuesday, November 25, at 2 p.m. Eastern, Weiss Members like you are invited to learn how to claim an early stake in the key company driving this disruption …

 … BEFORE any initial Public offering, or IPO.

This is going to be Weiss Ratings’ premier private investing event of the year.

Because this deal was personally selected by Weiss Ratings’ Private Deal Hunter, Chris Graebe.

Chris is an early-stage investor who’s invested alongside billionaires like Mark Cuban and Kevin O’Leary.

He’s put his money in 25+ private companies. These were startups valued at just a few million dollars in total when he first invested. Today, they’re worth a combined $1 billion and counting — including the ones that didn’t work out.

Since teaming up with Weiss Ratings, Chris has shown Weiss Members how to claim early stakes in what could be some of the hottest private deals in America …

Like Paladin Power, an energy tech company that scored a letter of intent for $240 million of new business … AFTER Weiss Members got to invest.

Taste of Nature, a confectionery company that landed a deal to sell its products in Costco locations nationwide …

A private aerospace service taking satellites to orbit for 92% cheaper than SpaceX … which recently announced its plan to IPO.

And a fully integrated uranium and small modular reactor company here in 2025 that quickly announced its plans to go public as well.

After an exhaustive period of due diligence, Chris believes this next deal could be the best one yet, for three reasons:

FIRST, this private company could RAPIDLY disrupt 3 fast-growing biomedical markets valued at over $700 billion (and that’s just the beginning) …

This company has created a breakthrough medical technology that is about to disrupt not one, not two … but THREE global markets … setting the stage for a HUGE potential win for early investors.

This company’s breakthrough holds extraordinary implications on eye function, sleep and expanding not just lifespans … but health spans.

In other words … providing healthier, longer lives for users at the cellular level.

This is not mere hype, our own Weiss Ratings CEO Dallas Brown says he has personally benefitted from this type of revolutionary development.

A former D1 Basketball player with chronic joint pain, Dallas says he can now play sports in his 40s thanks to this biomedical breakthrough.

On top of this, the company in Chris’ crosshairs has outstanding leadership. They’ve proven they can deliver on their lofty promises.

A team of industry veterans with a track record of growing companies FAST and taking them public, offering early investors a chance at life-changing returns.

They’ve already built multiple successful biomedical companies that led to huge acquisitions and Initial Public Offerings, including the 4th largest life sciences IPO EVER, which was valued at $1.3 billion.

But this newest innovation looks to be its biggest win yet.

Better yet, future profits will be protected as this company has secured patents through 2046.

After intensive vetting, meeting with the founders and visiting their labs in person …

Chris believes this new company that Weiss Members get to invest in could be the next great success story.

And everyone who joins us on Tuesday, Nov. 25, has a chance to claim private shares in this company BEFORE any IPO ever occurs. 

SECOND, private deal shares are NOT affected by market volatility.

2025 has been a roller-coaster ride for investors, to say the least. We all know that this market can turn on a dime. And that’s what makes this opportunity perfect for this moment in history.

Unlike regular stocks, investments in private company shares are insulated from the daily ups and downs and drama of the market.

If you’re looking for a less volatile place to put your money, private deals are the right opportunity at the right time.

Especially this one, because …

THIRD, this is no ordinary private deal. It’s an Alpha Round deal.

The Alpha Round is one of the earliest rounds of funding … and historically, it’s one that has produced some of the greatest possible returns.

This is an opportunity that used to be reserved only for the most well-connected angel investors and venture capital firms. But now … it’s yours.

How much of an advantage does being such an early private investor give you? Consider these real cases:

• IPO investors in Facebook (Meta) could’ve made 5,574% … but one Alpha Round investor made over 297,000% returns (53 times more).
• IPO investors in Cytek Biosciences are down over 72%. But even with that stock doing poorly, the early investors are still up 1,952%. Enough to turn a $10,000 stake into $205,200.
• IPO investors in one company Chris will reveal could have made 562% … but Alpha Round investors are up as much as 37,989% … over 67 TIMES greater returns … enough to turn a $10,000 investment into more than $3.8 million.

Looking ahead, no one can promise investors will make THAT much money. And of course, losses are also possible.

But we DO promise you a seat at the table …

At the Alpha Round level.

And you’ll have access the very first day the deal opens.

That means you’ll have the chance to invest …

Before angel investors …

Before venture capital firms …

Before any giant investment banks get a seat at the table.

It all starts on Tuesday, November 25, at 2 p.m. Eastern.

Here’s everything you need to know:

Then, check your inbox for my confirmation email with the link and instructions to attend.

Plus, we’ll be following up via email or text messages with exciting materials and videos to help you prepare for this major event.

We can’t wait to see you there!

John Burke,
Host
Weiss Ratings Presents: The $706 Billion Private Deal Briefing